tetano
Editor, Senior Moderator
Vaccine. 2019 Oct 25. pii: S0264-410X(19)31417-3. doi: 10.1016/j.vaccine.2019.10.044. [Epub ahead of print] [h=1]Protective efficacy of vaccines of the Korea national antigen bank against the homologous H5Nx clade 2.3.2.1 and clade 2.3.4.4 highly pathogenic avian influenza viruses.[/h]
Kang YM[SUP]1[/SUP], Cho HK[SUP]1[/SUP], Kim HM[SUP]1[/SUP], Lee MH[SUP]1[/SUP], To TL[SUP]2[/SUP], Kang HM[SUP]3[/SUP].
[h=3]Author information[/h] 1 Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon-si, Gyeongsangbuk-do 39660, Republic of Korea. 2 National Center for Veterinary Diagnostics, No. 11, 78th Lane, GiaiPhong Road, Dong Da, Hanoi, Viet Nam. 3 Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon-si, Gyeongsangbuk-do 39660, Republic of Korea. Electronic address: greenkang@korea.kr.
[h=3]Abstract[/h] The occurrence of severe outbreaks of highly pathogenic avian influenza in Korea led to establishment of a national antigen bank for emergency preparedness. Here, we developed five vaccines for this bank (clade 2.3.2.1C, clade 2.3.4.4A, B, C, and D) by reverse genetics, inactivated them with formalin, and evaluated the protective efficacy and potency of serial dilutions against lethal homologous challenge in specific-pathogen-free chickens. After vaccination with one dose, each vaccine resulted in 100% survival, with no clinical symptoms, or lack of detectable virus shedding, and high levels of pre-challenge protective immunity (8.4-10.2 log[SUB]2[/SUB]). After vaccination with one-tenth of the full dose, protection was similar to that with the full dose. After vaccination with one-hundredth of the initial dose, survival was 20-80%, and all vaccines showed virus shedding. Four vaccines (excluding clade 2.3.2.1C) had satisfactory potency. In antibody-persistence tests, all vaccines maintained long-lasting protective immunity. Our results suggest that inactivated reverse-genetics vaccines genetically matched to outbreak viruses provide adequate protection after a single vaccination.
Copyright ? 2019 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Antigen bank; Chicken; Highly pathogenic avian influenza; Inactivation; Vaccine
PMID: 31669062 DOI: 10.1016/j.vaccine.2019.10.044
Kang YM[SUP]1[/SUP], Cho HK[SUP]1[/SUP], Kim HM[SUP]1[/SUP], Lee MH[SUP]1[/SUP], To TL[SUP]2[/SUP], Kang HM[SUP]3[/SUP].
[h=3]Author information[/h] 1 Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon-si, Gyeongsangbuk-do 39660, Republic of Korea. 2 National Center for Veterinary Diagnostics, No. 11, 78th Lane, GiaiPhong Road, Dong Da, Hanoi, Viet Nam. 3 Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon-si, Gyeongsangbuk-do 39660, Republic of Korea. Electronic address: greenkang@korea.kr.
[h=3]Abstract[/h] The occurrence of severe outbreaks of highly pathogenic avian influenza in Korea led to establishment of a national antigen bank for emergency preparedness. Here, we developed five vaccines for this bank (clade 2.3.2.1C, clade 2.3.4.4A, B, C, and D) by reverse genetics, inactivated them with formalin, and evaluated the protective efficacy and potency of serial dilutions against lethal homologous challenge in specific-pathogen-free chickens. After vaccination with one dose, each vaccine resulted in 100% survival, with no clinical symptoms, or lack of detectable virus shedding, and high levels of pre-challenge protective immunity (8.4-10.2 log[SUB]2[/SUB]). After vaccination with one-tenth of the full dose, protection was similar to that with the full dose. After vaccination with one-hundredth of the initial dose, survival was 20-80%, and all vaccines showed virus shedding. Four vaccines (excluding clade 2.3.2.1C) had satisfactory potency. In antibody-persistence tests, all vaccines maintained long-lasting protective immunity. Our results suggest that inactivated reverse-genetics vaccines genetically matched to outbreak viruses provide adequate protection after a single vaccination.
Copyright ? 2019 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Antigen bank; Chicken; Highly pathogenic avian influenza; Inactivation; Vaccine
PMID: 31669062 DOI: 10.1016/j.vaccine.2019.10.044